Literature DB >> 9618244

Enhanced vasorelaxation by overexpression of beta 2-adrenergic receptors in large arteries.

M A Gaballa1, K Peppel, R J Lefkowitz, M Aguirre, P C Dolber, G D Pennock, W J Koch, S Goldman.   

Abstract

This study was designed to determine if adenoviral-mediated delivery of a transgene encoding the beta 2-adrenergic receptor (beta 2-AR) to the carotid arterial wall could result in alterations in in vivo vascular function. De-endothelialized rat carotid arteries were infused in vivo with 0.1 mg/ml elastase and adenovirus [6 x 10(9) plaque forming units (PFU)] containing either the marker gene beta-galactosidase (Adeno-beta-gal), DNA encoding the human beta 2-AR (Adeno-beta 2-AR), or no transgene. This low concentration of elastase increased the water permeability (5.2 +/- 0.6 v 1.9 +/- 0.4 x 10(-8) cm/s/mmHg, n = 4, P < 0.0001) without affecting either the vasomotor responsiveness or the morphology of the arterial wall. A transfection efficiency of 73% was achieved with Adeno-beta-gal (n = 3). beta-gal expression was associated with infrequent appearance of T and B lymphocytes, or neutrophil infiltration. Five days after infection with Adeno-beta 2-AR, the total beta-AR density increased six-fold (67.8 +/- 3.4 v 397.0 +/- 155.5 fmol/mg protein, n = 5, P < 0.01); isoproterenol-induced vasorelaxation at transmural pressures from 10-110/mmHg increased (P < 0.01) compared to arteries exposed to control virus (empty adenovirus), n = 4; and isoproterenol-stimulated cAMP production was increased by 65% (n = 5). Thus, adenoviral-mediated delivery of beta 2-ARs into large artery walls results in enhanced beta-AR-mediated vasorelaxation via augmentation in cAMP levels in vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618244     DOI: 10.1006/jmcc.1998.0668

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

1.  The Arg16Gly polymorphism of the beta2-adrenergic receptor and the natriuretic response to rapid saline infusion in humans.

Authors:  Eric M Snyder; Stephen T Turner; Michael J Joyner; John H Eisenach; Bruce D Johnson
Journal:  J Physiol       Date:  2006-05-25       Impact factor: 5.182

2.  Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis.

Authors:  G Iaccarino; L A Smithwick; R J Lefkowitz; W J Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans.

Authors:  Eric M Snyder; Kenneth C Beck; Niki M Dietz; John H Eisenach; Michael J Joyner; Stephen T Turner; Bruce D Johnson
Journal:  J Physiol       Date:  2005-12-08       Impact factor: 5.182

4.  Differential vulnerabilities of urethral afferents in diabetes and discovery of a novel urethra-to-urethra reflex.

Authors:  Zhongguang Yang; Paul C Dolber; Matthew O Fraser
Journal:  Am J Physiol Renal Physiol       Date:  2009-10-28

5.  Altered beta-2 adrenergic receptor gene expression in human clinical hypertension.

Authors:  Jennifer R Dungan; Yvette P Conley; Taimour Y Langaee; Julie A Johnson; Shawn M Kneipp; Philip J Hess; Carolyn B Yucha
Journal:  Biol Res Nurs       Date:  2009-03-01       Impact factor: 2.522

6.  Beta-Adrenergic gene therapy for cardiovascular disease.

Authors:  Andrea D Eckhart; Walter J Koch
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

7.  Cardiovascular changes after administration of aerosolized salbutamol in horses: five cases.

Authors:  Daniela Casoni; Claudia Spadavecchia; Chiara Adami
Journal:  Acta Vet Scand       Date:  2014-08-14       Impact factor: 1.695

8.  Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer.

Authors:  Stacie M Jones; F Charles Hiller; Sandie E Jacobi; Susan K Foreman; Laura M Pittman; Lawrence E Cornett
Journal:  BMC Pharmacol       Date:  2003-12-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.